Circulating B vitamins metabolites in depressive disorders - connections with the microbiota-gut-brain axis
Behavioural Brain Research,
Journal Year:
2024,
Volume and Issue:
472, P. 115145 - 115145
Published: July 9, 2024
Language: Английский
Microbiome dysbiosis in SARS-CoV-2 infection: implication for pathophysiology and management strategies of COVID-19
Frontiers in Cellular and Infection Microbiology,
Journal Year:
2025,
Volume and Issue:
15
Published: April 22, 2025
The
emergence
of
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2),
the
etiological
agent
disease
2019
(COVID-19),
in
late
initiated
a
global
health
crisis
marked
by
widespread
infection,
significant
mortality,
and
long-term
implications.
While
SARS-CoV-2
primarily
targets
system,
recent
findings
indicate
that
it
also
significantly
disrupts
human
microbiome,
particularly
gut
microbiota,
contributing
to
severity,
systemic
inflammation,
immune
dysregulation,
increased
susceptibility
secondary
infections
chronic
conditions.
Dysbiosis,
or
microbial
imbalance,
exacerbates
clinical
outcomes
COVID-19
has
been
linked
long-COVID,
condition
affecting
proportion
survivors
manifesting
with
over
200
symptoms
across
multiple
organ
systems.
Despite
growing
recognition
microbiome
alterations
COVID-19,
precise
mechanisms
which
interacts
influences
progression
remain
poorly
understood.
This
narrative
review
investigates
impact
on
host-microbiota
dynamics
evaluates
its
implications
severity
for
developing
personalized
therapeutic
strategies
COVID-19.
Furthermore,
highlights
dual
role
modulating
progression,
as
promising
target
advancing
diagnostic,
prognostic,
approaches
managing
Language: Английский
Elevated risk of adverse effects from foodborne contaminants and drugs in inflammatory bowel disease: a review
Archives of Toxicology,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Sept. 9, 2024
Abstract
The
global
burden
of
Inflammatory
bowel
disease
(IBD)
has
been
rising
over
the
last
decades.
IBD
is
an
intestinal
disorder
with
a
complex
and
largely
unknown
etiology.
characterized
by
chronically
inflamed
gastrointestinal
tract,
intermittent
phases
exacerbation
remission.
This
compromised
barrier
can
contribute
to,
enhance,
or
even
enable
toxicity
drugs,
food-borne
chemicals
particulate
matter.
review
discusses
whether
prevalence
in
our
society
warrants
consideration
patients
as
specific
population
group
toxicological
safety
assessment.
Various
vivo,
ex
vivo
vitro
models
are
discussed
that
simulate
hallmarks
may
be
used
to
study
effects
prevalent
inflammation
on
hazards
these
various
toxicants.
In
conclusion,
risk
assessments
based
healthy
individuals
not
sufficiently
cover
patient
it
suggested
consider
this
susceptible
subgroup
future
assessments.
Language: Английский
Intestinal Cells-on-Chip for Permeability Studies
Micromachines,
Journal Year:
2024,
Volume and Issue:
15(12), P. 1464 - 1464
Published: Nov. 30, 2024
Background:
To
accurately
measure
permeability
of
compounds
in
the
intestine,
there
is
a
need
for
preclinical
vitro
models
that
represent
specificity,
integrity
and
complexity
human
small
intestinal
barrier.
Intestine-on-chip
systems
hold
considerable
promise
as
testing
platforms,
but
several
characteristics
still
require
optimization
further
development.
Methods:
An
established
intestine-on-chip
model
tissue
explants
was
adopted
cell
monolayer
culture.
A
3D-printed
culture
disc
designed
to
allow
static
conditions
subsequent
studies
dynamic
environment.
Membrane
standardized
read-outs
were
investigated
compared
traditional
under
conditions.
Results:
By
starting
cultures
outside
chip
conventional
wells
plates,
new
design
could
support
accurate
formation
both
Caco-2
enteroids.
When
transferred
with
laminar
flow,
detection
barrier
(FD4
Cascade
Blue)
(atenolol/antipyrine).
Both
flow
membrane
had
significant
impact
on
outcomes.
Conclusions:
This
novel
cell-on-chip
system
offers
large
flexibility
studies,
although
it
requires
validation
more
reveal
its
full
potential.
Language: Английский
Leveraging Organ‐on‐Chip Models to Investigate Host–Microbiota Dynamics and Targeted Therapies for Inflammatory Bowel Disease
Advanced Healthcare Materials,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Nov. 3, 2024
Abstract
Inflammatory
bowel
disease
(IBD)
is
an
idiopathic
gastrointestinal
with
drastically
increasing
incidence
rates.
Due
to
its
multifactorial
etiology,
a
precise
investigation
of
the
pathogenesis
extremely
difficult.
Although
reductionist
cell
culture
models
and
more
complex
in
animals
have
clarified
understanding
individual
mechanisms
contributing
factors
IBD
past,
it
remains
challenging
bridge
research
clinical
practice.
Conventional
2D
cannot
replicate
host–microbiota
interactions
stable
long‐term
microbial
culture.
Further,
extrapolating
data
from
animal
patients
due
genetic
environmental
diversity
leading
differences
immune
responses.
Human
intestine
organ‐on‐chip
(OoC)
emerged
as
alternative
vitro
model
approach
investigate
IBD.
OoC
not
only
recapitulate
human
intestinal
microenvironment
accurately
than
cultures
yet
may
also
be
advantageous
for
identification
important
disease‐driving
pharmacological
interventions
targets
possibility
emulating
different
complexities.
The
predispositions
biological
hallmarks
focusing
on
at
mucosal
barrier
are
elucidated
here.
Additionally,
potential
OoCs
explore
microbiota‐related
therapies
personalized
medicine
treatment
discussed.
Language: Английский